Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 2026
10.10.2026 18:09:00 CEST | Business Wire | Press Release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/
Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani.
The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes.
“I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake, but to listen to physicians, understand what they need in the operating room and work with a team capable of turning those needs into something real,” said Filippo Fagnani.
An engineer by training and not a urologist, Fagnani has dedicated his professional life to understanding the intersection between clinical needs and technological development. Over the years, this approach has contributed to a series of innovations in laser urology, including Vapor Tunnel®, Virtual Basket® and, more recently, Quanta Magneto™ Technology.
Together, these developments reflect a broader vision of the operating room: an increasingly connected surgical environment in which technologies, instruments and clinical expertise work together to give physicians greater control and flexibility.
For Fagnani, however, innovation has never been an individual achievement. At Quanta System, innovation begins with listening to clinical needs and takes shape through the collective expertise of urologists and multidisciplinary teams spanning research and development, engineering, marketing and every area of the company. This integrated approach helps turn ideas and strategic vision into technologies that offer physicians greater flexibility and control in the operating room.
“An idea can start with one person, but innovation is never the work of one person. What makes a vision meaningful is the ability of a team to turn it into something that doctors can use and patients can benefit from. I am proud of what we have achieved together, and even more motivated by what is still possible,” Fagnani added.
The recognition at ICE26 follows the inaugural 2025 Award for Significant Contribution to Endourology, presented to Dr. Gregory Altshuler for his pioneering contribution to laser technology in urology.
“Great innovation starts with a vision and becomes meaningful through teamwork. Congratulations to Filippo on this well-deserved recognition for his contribution to endourology. Proud of the team behind this journey,” said Girolamo Lionetti, CEO of Quanta System.
This recognition reflects Quanta System’s ongoing commitment to connecting technology, clinical expertise and the needs of the operating room, with patient safety at the heart of every innovation.
Quanta System S.p.A.
For almost 40 years, Quanta System, a 100% Italian company operating worldwide, has been a reference point in the research, design and manufacture of state-of-the-art laser systems for surgery, dermatology, aesthetic medicine and art conservation.
In 2004, the company joined El.En. SpA (ELN), a leader in the laser market listed on Euronext STAR Milan.
Designed for doctors, specialised operators and restorers, Quanta System lasers are recognised as the “Gold Standard” thanks to their wide range of applications.
Entirely manufactured in Italy at the company’s headquarters in Samarate, near Varese, each system reflects a commitment to innovation and quality, from R&D to production. Through close collaboration with professionals worldwide, Quanta System develops solutions that meet their evolving needs, helping improve patient care and contribute to a better quality of life.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261010101303/en/
Contacts
Tel. +39 3429773727
E-mail eleonora.disalvo@quantasystem.com
Website www.quantasystem.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.quantasyste
m.com&esheet=54619656&newsitemid=20261010101303&lan=en-US&anchor=www.quantasyste
m.com&index=1&md5=8057f5e6779f9eddff2a7c652c2e20fa
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press Release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press Release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press Release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press Release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom